Clinical Pharmacology &Therapeutics, EarlyView.We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi +100 more
wiley +1 more source
RORγt‐APCs: The New Masters of Oral Tolerance
Barrier Immunity, EarlyView.ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley +1 more source
Negative patch test findings after initiation of upadacitinib: A case report
SAGE Open Medical Case ReportsUpadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis.
Meghan L McPhie +2 more
doaj +1 more source
Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature
Pulmonary Circulation, 2019 Background Pulmonary arterial hypertension consists in an increase of mean pulmonary arterial pressure (PAPm ≥ 25 mmHg), and may lead to right ventricular failure.
A. Trombetta +7 more
doaj +1 more source
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib [PDF]
, 2023 Robert Harrington +2 more
openalex +1 more source
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
, 2013 This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J. +3 more
openaire +2 more sources
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Role of Janus kinase-2 in insulin-mediated phosphorylation and inactivation of protein phosphatase-2A and its impact on upstream insulin signalling components [PDF]
, 1999 Najma BEGUM, Louis Ragolia
openalex +1 more source
Herpes zoster subunit vaccine for patients initiating a Janus kinase inhibitor [PDF]
, 2022 Reid A. Waldman +3 more
openalex +1 more source